Kenvue (KVUE) faces significant regulatory and reputational headwinds as the Trump administration asserted, without evidence, a definitive link between acetaminophen, the active ingredient in pain reliever Tylenol, and autism during pregnancy. This represents a direct challenge to one of Kenvue's most important revenue drivers within its Self-Care segment, which includes trusted brands such as Tylenol, Motrin, and Benadryl. The consumer health company, spun off from Johnson & Johnson (JNJ) in 2023, has re ...